ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem
20.10.2026 15:00:00 EEST | Business Wire | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value.
While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls.
Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate.
The importance of this operational understanding is reinforced by new research conducted by The Hackett Group and ARIS. In a survey of more than 200 business executives at Global 2000 organizations, 82% agreed that Process Context is required for deploying AI agents, yet only 21% reported comprehensive, real-time visibility into how work flows across their enterprise. Crucially, organizations using Process Context tools were more than five times as likely to report measurable ROI from their AI investments.
“Enterprise AI is entering a new phase, and the question for business leaders has rapidly shifted from ‘Where can we deploy AI?’ to ‘Where can AI create the greatest value?’” said Guillaume Bacuvier, CEO, ARIS. “The research exposes the challenge: businesses recognize that AI needs to understand how they operate, but most still lack that foundation. ARIS bridges this gap by providing the Process Context that agents need to work effectively – helping enterprises identify where AI can make the biggest impact, accelerate deployment and deliver measurable new business outcomes.”
ARIS Process Context for Enterprise AI reinforces this strategic role:
- Object-Centric Process Mining (OCPM): Significantly expands the depth of operational insight available, helping companies connect a broader picture of how work is designed with increasingly detailed evidence of how it actually happens – strengthening the Digital Twin of the Organization.
- Process Lens: Identifies where AI will have the greatest impact across the enterprise, enabling organizations to make a faster and more informed start with Enterprise AI and deliver measurable ROI.
Model Context Protocol (MCP): Process Context for Enterprise AI enables AI agents and applications to access trusted Process Context – the processes, roles, systems, rules, risks and controls that determine what should happen and under what conditions – through the ARIS platform.
“AI agents are only as effective as their understanding of the environment in which they're being asked to operate,” said Maxime Hambersin, Chief Product Officer, ARIS. “Our latest release brings together three critical capabilities that create a powerful, governed foundation for moving from isolated AI use cases toward scalable, controlled and value-driven agentic AI.”
ARIS Process Context for Enterprise AI is available from October 26.
About ARIS
ARIS is the Process Context Platform for Enterprise AI. Based on its powerful Enterprise Model, ARIS connects processes, people, systems, risks and controls with real-world execution data to create a governed Digital Twin of the Organization. This unique foundation enables Global 2000 enterprises to improve operational performance, identify where AI delivers the greatest value, and give agents the trusted business context they need to act reliably and cost-effectively. For more information, visit www.aris.com.
About the research
The Process Context Study 2026 was conducted by The Hackett Group in collaboration with ARIS. It surveyed 200 respondents at large and multinational organisations across North America (45%), Europe (34%) and the rest of the world (21%). 80% of participating organisations have revenue over $1 billion and 60% have more than 10,000 employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261020061500/en/
Contacts
Media Contact
Andrew Tongue, Head of PR, Content & Media
Andrew.tongue@aris.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
Visa, BILL and Billtrust Launch First Live Pilot for Trusted AI Agent Payments Between Buyer and Supplier Platforms20.10.2026 15:00:00 EEST | Press release
Visa (NYSE: V), BILL (NYSE: BILL) and Billtrust today announced they have launched the first live pilot to enable trusted AI agents to initiate and complete approved buyer invoice payments end-to-end through supplier portals. Until now, many payment portals relied on human authentication requirements that limited how approved payments could be automated. Together, with leading accounts payable and receivable solutions providers BILL and Billtrust, the Visa Intelligent CommerceTM portfolio helps bridge that gap. Leveraging offerings such as Visa Trusted Agent Protocol, AI agents can now be securely authenticated to credentialed portals. As a result, buyer payments that previously relied on manual entry can be completed by trusted AI agents, while preserving supplier control and oversight. How trusted AI agents are overcoming one of payment automation’s biggest barriers The flow begins when the authorized BILL Payment Agent — registered using Visa’s Trusted Agent Protocol and Agentic Dir
FiRa Consortium Launches Core 4.1 Specifications and Enhanced Certification Program20.10.2026 15:00:00 EEST | Press release
The FiRa® Consortium today announced the release of the FiRa Core 4.1 Specifications and an updated 4.1 Certification Program to help advance ultra-wideband (UWB) interoperability within the FiRa ecosystem. Core 4.1 introduces enhancements for FiRa Untracked Navigation, expanded cryptographic security certification, and additional support for concurrent ranging and data capabilities across multi-vendor FiRa deployments. The release supports deployment requirements defined by the FiRa Frameworks and Profiles Sub-Group (FPSG), including high-density indoor positioning, hardware-level security, and concurrent data capabilities for FiRa use cases. Features of the FiRa Core 4.1 Specifications and Certification Program Enhanced Downlink Time Difference of Arrival (DL-TDoA) for FiRa Untracked Navigation — Adds coordinate-system and anchor-location encoding options, including floor identification without increasing message size, with certification coverage for these options and cross-cluster s
Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility20.10.2026 15:00:00 EEST | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overall cost. Evercode MAX enables researchers to build a kit configuration around their experiment, with sample barcoding and library preparation as independent kits. Evercode MAX is available for Whole Transcriptome, WT FFPE, TCR, BCR, and CRISPR Detect. With configurations supporting up to 384 samples and 2 million cells, researchers can prioritize more samples to characterize biological variation or more cells per sample to resolve rare populations and subtle cell states. That flexibility extends to value as well. Because E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom